Elanco Animal Health (NYSE:ELAN) Shares Down 8.2% – What’s Next?

Posted by Geri Gentry on May 13th, 2026

Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) dropped 8.2% during mid-day trading on Monday . The stock traded as low as $21.86 and last traded at $21.72. Approximately 5,032,741 shares traded hands during mid-day trading, a decline of 1% from the average daily volume of 5,100,093 shares. The stock had previously closed at $23.65.

Wall Street Analysts Forecast Growth

ELAN has been the topic of several recent analyst reports. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 18th. JPMorgan Chase & Co. raised their target price on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Morgan Stanley lifted their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $24.00 to $30.00 in a research report on Thursday, January 22nd. Finally, KeyCorp lifted their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.20.

Check Out Our Latest Analysis on ELAN

Elanco Animal Health Stock Up 1.9%

The company’s fifty day moving average price is $23.47 and its 200-day moving average price is $23.36. The stock has a market capitalization of $10.91 billion, a PE ratio of -43.67, a price-to-earnings-growth ratio of 2.29 and a beta of 1.69. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. During the same period last year, the business earned $0.37 earnings per share. The business’s revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Analysts forecast that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds have recently added to or reduced their stakes in ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Elanco Animal Health in the 1st quarter worth approximately $2,065,000. Goldman Sachs Group Inc. boosted its holdings in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after buying an additional 2,445,872 shares during the period. Empowered Funds LLC boosted its holdings in Elanco Animal Health by 35.2% in the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after buying an additional 4,121 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after buying an additional 76,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Elanco Animal Health by 2,006.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock valued at $4,432,000 after purchasing an additional 295,651 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

(Get Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.